Allergan plc said the U.s. Food and Drug Administration cleared ZELTIQ Aesthetics Inc.'s nonsurgical fat reduction CoolSculpting technology to improve the appearance of lax tissue in combination with submental fat, or double chin.
CoolSculpting for the double chin is clinically proven to reduce fat up to 20% in the treated area after one treatment, according to the company.
The company said a clinical study of CoolSculpting in submental fat treatment found that 77% of patients showed an improved appearance of lax tissue and 75% of patients reported their chin looked more toned after treatment.
Allergan acquired ZELTIQ Aesthetics for $2.47 billion in April.
